Takeda has been ordered to pay $885m – potentially rising to $2.5bn – after a landmark court case verdict found the Japanese pharma company liable for a conspired arrangement ...

SERB Pharmaceuticals has signed an agreement to acquire exclusive development and commercialisation rights to Idefirix from Hansa Biopharma for a total of $133.6m.

The UK has received doses of antiviral medicine favipiravir as a precaution in case hantavirus spreads in the country. The medicine, developed by Fujifilm subsidiary Toyama Chemical in Japan, has been ...

Regeneron Pharmaceuticals has signed a $2.32bn deal with Parabilis Medicines to develop therapeutic candidates, with a focus on AHCs.

ITALVACUUM will participate in EXPOQUIMIA 2026, taking place in Barcelona from 2 to 5 June, where the company will present its vacuum drying technologies developed for pharmaceutical and ...

The WHO has classed this outbreak as “extraordinary” due to the lack of therapeutic options and epidemiological trends.

Boehringer Ingelheim has received Japan’s MHLW approval for Jascayd (nerandomilast) to treat adults with IPF and PPF.

The wider US HHS is going through a leadership upheaval, as Republicans aim to keep voters on side amid the looming midterm elections.

Ovarian cancer research is entering a pivotal era characterized by increasing complexity for large, global studies.

The FDA has approved Daiichi Sankyo and AstraZeneca’s Enhertu for two new indications in HER2-positive early breast cancer.

At ECO 2026, findings from a post-hoc indirect treatment comparison of Wegovy versus Foundayo, oral GLP-1RAs approved in the US for chronic weight management.

During ECO 2026, a study was presented analysing the use of tirzepatide, a dual GIP and GLP-1 agonist, in treating type 1 diabetes (T1D).